Kurtoglu Metin

SEC source: 0001453687-25-000040 · wk-form4_1736298335.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,258

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-25-000040 · wk-form4_1736298335.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,716

F1 · price: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees.

SEC source: 0001453687-25-000018 · wk-form4_1736198370.xml · derivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,400

Underlying: Common Stock · 47,400 shares

Expires 2035-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

SEC source: 0001453687-25-000018 · wk-form4_1736198370.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,133

F1 · acquired: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · derivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,099

Underlying: Common Stock · 2,901 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 5.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,934

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · derivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,000

Underlying: Common Stock · 10,763 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F4 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 5.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.58 to $26.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,572

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.58 to $25.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000145 · wk-form4_1733952508.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,796

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 10

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,763

Underlying: Common Stock · 32,789 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.50 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 9

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,552

Underlying: Common Stock · 5,700 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,133

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.01 to $17.98. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,733

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · derivative · entry 8

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,252

Underlying: Common Stock · 200 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F3 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 4.

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

SEC source: 0001453687-24-000140 · wk-form4_1732233135.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 11

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,452

Underlying: Common Stock · 34,400 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 8

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.50 to $18.69. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,761

F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.50 to $18.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,433

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 10

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,852

Underlying: Common Stock · 22,068 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,101

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · derivative · entry 9

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,920

Underlying: Common Stock · 25,900 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · price: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.

F6 · derivative.exercise_date: The option was fully vested and exercisable upon the closing of the merger described in footnote 7.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,033

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $17.00 to $17.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,033

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $16.00 to $16.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001453687-24-000132 · wk-form4_1731976349.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,933

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 7

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,254

Underlying: Common Stock · 14,254 shares

Expires 2032-02-29

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Following the Automatic Conversion, options previously exercisable for shares of Series A Preferred Stock may be exercised solely for shares of Common Stock.

F7 · derivative.exercise_date: Following the Automatic Conversion, the option is currently exercisable for 7,127 shares of Common Stock and becomes exercisable for the remaining 7,127 shares of Common Stock in two equal tranches on March 1, 2025 and 2026.

F1 · derivative.underlying_shares: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 6

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Non-Voting Convertible Preferred Stock · 427.646 shares

Expires 2033-01-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F6 · derivative.exercise_date: Prior to the Automatic Conversion, the option was exercisable for 213.823 shares of Series A Preferred Stock and would have become exercisable for the remaining 213.823 shares of Series A Preferred Stock in two equal tranches on March 1, 2025 and 2026.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 5

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,254

Underlying: Common Stock · 14,254 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Following the Automatic Conversion, options previously exercisable for shares of Series A Preferred Stock may be exercised solely for shares of Common Stock.

F4 · derivative.exercise_date: Following the Automatic Conversion, the option is fully exercisable.

F1 · derivative.underlying_shares: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 4

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Non-Voting Convertible Preferred Stock · 427.645 shares

Expires 2031-04-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F2 · derivative.exercise_date: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the Reverse Stock Split and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. Prior to the Automatic Conversion, the option was fully exercisable.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 213,820

Underlying: Common Stock · 213,820 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · price: Following the Automatic Conversion, options previously exercisable for shares of Series A Preferred Stock may be exercised solely for shares of Common Stock.

F4 · derivative.exercise_date: Following the Automatic Conversion, the option is fully exercisable.

F1 · derivative.underlying_shares: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

F1 · balance_after: On April 4, 2024, the issuer effected a 1-for-30 reverse stock split (the "Reverse Stock Split") of its common stock ("Common Stock"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

SEC source: 0001453687-24-000057 · wk-form4_1712799040.xml · derivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Series A Non-Voting Convertible Preferred Stock · 6,414.682 shares

Expires 2026-11-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F2 · derivative.exercise_date: On March 27, 2024, the issuer held a special meeting of stockholders (the "Special Meeting"). At the Special Meeting, the stockholders of the issuer approved the Reverse Stock Split and the conversion of the issuer's Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") into shares of Common Stock. On April 8, 2024, the conversion of the majority of the shares of Series A Preferred Stock occurred automatically (the "Automatic Conversion"). The remaining shares of Series A Preferred Stock remain subject to certain beneficial ownership limitations described in the issuer's filings with the Securities and Exchange Commission. Prior to the Automatic Conversion, the option was fully exercisable.

SEC source: 0001453687-24-000016 · wk-form4_1704405809.xml · derivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,965,000

Underlying: Common Stock · 1,965,000 shares

Expires 2034-01-01

F2 · derivative.exercise_date: This option vests as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.

SEC source: 0001453687-24-000016 · wk-form4_1704405809.xml · nonDerivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,531,000

F1 · kind: Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2025. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2028.

SEC source: 0001062993-23-020924 · form4.xml · derivative · entry 3

Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427.645

Underlying: Series A Non-Voting Convertible Preferred Stock · 427.645 shares

Expires 2032-02-29

F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F4 · derivative.exercise_date: Option is currently exercisable for 106.911 shares of Series A Non-Voting Convertible Preferred Stock of the issuer ("Series A Preferred Stock") and becomes exercisable for the remaining shares in three equal tranches on March 1, 2024, 2025 and 2026.

F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

SEC source: 0001062993-23-020924 · form4.xml · derivative · entry 2

Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427.645

Underlying: Series A Non-Voting Convertible Preferred Stock · 427.645 shares

Expires 2031-04-25

F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F1 · derivative.exercise_date: Option is fully exercisable.

F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

SEC source: 0001062993-23-020924 · form4.xml · derivative · entry 1

Kurtoglu Metin · CIK 0002000284 · Chief Operations Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,414.682

Underlying: Series A Non-Voting Convertible Preferred Stock · 6,414.682 shares

Expires 2026-11-06

F3 · price: On November 13, 2023, the issuer acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Cartesian common stock held by the reporting person were converted into options to purchase shares of Series A Preferred Stock in connection with the acquisition.

F1 · derivative.exercise_date: Option is fully exercisable.

F2 · derivative.underlying: Following the approval by the stockholders of the issuer of the conversion of the Series A Preferred Stock into shares of common stock of the issuer ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.